LEO Pharma Seeks Start-Ups To Venture ‘Beyond The Pill’
This article was originally published in Clinica
One of Europe’s long-established pharma players in the dermatology market has ring-fenced £45m ($65m) across a three-year period to back start-ups developing non-drug solutions for psoriasis patients. These could include apps, wearables and other technologies and services that could improve management of this autoimmune disease.
Register for our free email digests: